SCHEMBL2716385

SCHEMBL2716385

CC(=O)Nc1cc(C(=O)NC(C)c2cnc(OCC(F)(F)F)c(C)c2)ccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 6/20 0.50
MAPT P10636 4/20 0.50
ACACB O00763 4/20 0.47
SCN9A Q15858 1/20 0.45
GSK3A P49840 3/20 0.44
ROCK2 O75116 4/20 0.41
AAK1 Q2M2I8 4/20 0.41
GAK O14976 1/20 0.41
CHRNA1 P02708 1/20 0.41
SLC6A2 P23975 1/20 0.41
CHRNA7 P36544 1/20 0.41
NR2C2 P49116 1/20 0.41
TAB1 Q15750 1/20 0.41
HIPK4 Q8NE63 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
BMP2K Q9NSY1 1/20 0.41
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2717176 0.92 ACACB (0.45) GSK3BMAPTACACBSCN9AGSK3A
SCHEMBL18266121 0.92 GSK3B (0.45) GSK3BMAPTACACBSCN9AGSK3A
SCHEMBL2713908 0.92 GSK3B (0.61) GSK3BMAPTACACBSCN9AGSK3A
SCHEMBL2715934 0.91 GSK3B (0.49) GSK3BMAPTACACBSCN9AGSK3A
SCHEMBL2713653 0.91 GSK3B (0.50) GSK3BMAPTACACBSCN9AGSK3A
SCHEMBL2713944 0.91 GSK3B (0.47) GSK3BMAPTACACBSCN9AGSK3A
SCHEMBL2716135 0.90 SCN9A (0.52) GSK3BMAPTACACBSCN9AGSK3A
SCHEMBL2715942 0.89 GSK3B (0.58) GSK3BMAPTGSK3A
SCHEMBL2715577 0.89 GSK3B (0.51) GSK3BMAPTACACBSCN9AGSK3A
SCHEMBL15350984 0.89 GSK3B (0.44) GSK3BMAPTACACBSCN9AGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP claimed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US claimed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US claimed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP claimed
CN-103249721-A Arylamine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC 2013-08-14 CN claimed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO claimed
CN-106478497-B Arylamine derivatives as TTX-S blockers 拉夸里亚创药株式会社 2020-05-08 CN disclosed
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP disclosed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP disclosed
CN-103249721-A Arylamine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC 2013-08-14 CN disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN2B, SCN1B, SCN2A GSK3B 4093/4885MAPT 3185/4885ACACB 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.